



Recording of stage and treatment data in Cancer Registries: a challenge but a step forward in Cancer Control

iPAAC 13-14 Dec 2021

www.kankerregister.org | www.registreducancer.org

Liesbet Van Eycken

iPAAC: Cancer Control in Europe: Finding Sustainable Solutions, 13-14.12.2021

Cancer Registries...

- “See their role more and more extended in Cancer Control Activities”
 - All ACTIONS to reduce the frequency & *impact* of cancer
 - primary prevention
 - screening
 - early diagnosis
 - treatment
 - rehabilitation
 - palliative care
 - Moving from monitoring cancer incidence to measuring outcomes




Cancer survival in Europe 1999–2007 by country and age: results of EURO CARE-5—a population-based study

Roberta De Angelis, Milena Sant, Michel P Coleman, Silvia Francisci, Paolo Baili, Daniela Pierannunzio, Annalisa Trama, Otto Visser, Hermann Brenner, Eva Ardanaz, Magdalena Bielska-Lasota, Gerda Engholm, Alice Nennecke, Sabine Siesling, Franco Berrino, Riccardo Capocaccia, and the EURO CARE-5 Working Group*



Lancet Oncol 2014; 15: 23–34

- ◆ Northern Europe
- UK and Ireland
- ▲ Central Europe
- ✦ Southern Europe
- Eastern Europe
- European average


Stomach




Colon




Lung



Skin melanoma



Breast



Survival results: Variability?

Organisation of healthcare

- Access to treatment
- Cancer screening programs
- Financial aspects

Implementation of and adherence to guidelines

- Quality of diagnosis and treatment
- Complexity of procedures and medical acts
- Influence of Age

Stage distribution

- Availability of information (methodology)
- Evolution of stage: Screening, early detection and diagnosis

“Analytical studies are needed to assess the effect of stage, staging practices, and treatment protocols on survival differences.”

De Angelis et al. Lancet Oncol 2014; 15: 23–34





INCLUDED in the DATASET:

- STAGE variables
- TREATMENT variables

Call for Data protocol for European population-based cancer registries

Organised by the European Commission's Joint Research Centre (JRC) and the
European Network of Cancer Registries (ENCR)


in collaboration with
the International Agency for Research on Cancer (IARC) and
EUROCARE

Projects served by the data call:


- European Cancer Information System (ECIS)
- Cancer Incidence in Five Continents (CI5-XII)
- EUROCARE-7

ENCR-JRC: Recommendations on 'Stage' for the Cancer Registries


1. Stage is a very important **prognostic factor** & should be included in population-based Cancer Registries
2. Use the international **TNM classification** and **Paediatric Cancer Stage Guidelines (Toronto)**
3. Apply the **general rules** of the TNM classification and the Paediatric Cancer Stage Guidelines
 1. Childhood (Toronto): Preferably TIER 2 (if resources are limited: tier 1)
4. Whenever possible, **register cTNM as well as (y)pTNM**
 1. The Canstaging + tool can be useful to facilitate TNM registration
5. Stage data needs validation and consistency checks
6. Specific training for data managers is needed
7. Resources are needed...



Head and Neck Cancer: relative survival by stage, Belgium, 2010-2019



Kidney Cancer Incidence: evolution stage, Belgium 2004-2019




Treatment

- **ENCR-JRC Call for Data 2021 Variables (1st course)**
- ENCR-JRC Working Group on TREATMENT data harmonisation in European Cancer Registries'
 - Work 'under construction'
- iPAAC WP 7: Pilot studies to integrate cancer registries data with administrative sources Tasks 7.2, 7.3 and 7.4

Treatment variables					
Surgery ^{8,9}	Resection of the primary tumour	F	1	9	0 → No 1 → Yes, without specification 2 → Yes, local surgery only ^a 3 → Yes, 'operative' surgery ^b
Rt	Radiotherapy	F	1	9	0 → No 1 → Yes, without specification 2 → Yes, neoadjuvant (pre-operative) radiotherapy 3 → Yes, adjuvant (post-operative) radiotherapy
Cht	Chemotherapy	F	1	9	0 → No 1 → Yes, without other specification 2 → Yes, neoadjuvant (pre-operative) 3 → Yes, adjuvant (post-operative) 4 → Yes, both neoadjuvant and adjuvant
Tt ¹⁰	Targeted therapy (including monoclonal antibodies)	F	1	9	0 → No 1 → Yes
It	Immunotherapy (excl. monoclonal antibodies)	F	1	9	0 → No 1 → Yes
Ht	Hormone therapy	F	1	9	0 → No 1 → Yes
Ot	Other or unspecified systemic therapy	F	1	9	0 → No 1 → Yes, without other specification 2 → Yes, neoadjuvant (pre-operative) 3 → Yes, adjuvant (post-operative)
SCT	Stem cell transplantation	F	1	9	0 → No 1 → Yes

Cancer Registries: Knowledge and Data Source for...



... in Cancer Control



Thank you!



The Cancer Registry is essential to cancer control, and cancer control is essential to (the survival of) the cancer registry.

Bruce K. Armstrong, 1992 Cancer Causes and Control, 3,569-579

iPAAC: Cancer Control in Europe: Finding Sustainable Solutions, 13-14.12.2021

Belgian Cancer Registry



www.kankerregister.org | www.registreducancer.org